131 related articles for article (PubMed ID: 36471533)
21. Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene?
Yamamoto M; Takeuchi K; Shimoji M; Maniwa T; Isaka M; Nakagawa K; Ohde Y; Kondo H; Nakajima T
Cancer Sci; 2012 Feb; 103(2):390-2. PubMed ID: 22296236
[TBL] [Abstract][Full Text] [Related]
22. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
23. Disseminated ALK-positive histiocytosis with
Qiu L; Weitzman SP; Nastoupil LJ; Williams MD; Medeiros LJ; Vega F
Leuk Lymphoma; 2021 May; 62(5):1234-1238. PubMed ID: 33353436
[No Abstract] [Full Text] [Related]
24. A novel fusion of TPR and ALK in lung adenocarcinoma.
Choi YL; Lira ME; Hong M; Kim RN; Choi SJ; Song JY; Pandy K; Mann DL; Stahl JA; Peckham HE; Zheng Z; Han J; Mao M; Kim J
J Thorac Oncol; 2014 Apr; 9(4):563-6. PubMed ID: 24736082
[TBL] [Abstract][Full Text] [Related]
25. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
26. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
27. Is Retention of the 5' Nononcogenic ALK Fusion Variant a Novel Poor Prognostic Factor in ALK-Positive NSCLC?
Hsiao SJ; Ou SI
J Thorac Oncol; 2020 Jul; 15(7):1103-1105. PubMed ID: 32593442
[No Abstract] [Full Text] [Related]
28. S100 and CD34 Expressing Mesenchymal Neoplasm With Rare PLEKHH2::ALK Fusion and Response to ALK Inhibition.
Coppock JD; Schneider MA; Surrey LF; Karakousis GC; Maki RG; Cooper K
Am J Surg Pathol; 2022 Sep; 46(9):1309-1313. PubMed ID: 35288525
[TBL] [Abstract][Full Text] [Related]
29. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
[TBL] [Abstract][Full Text] [Related]
30. Treatment of lung cancer with an ALK inhibitor after EML4-ALK fusion gene detection using endobronchial ultrasound-guided transbronchial needle aspiration.
Nakajima T; Kimura H; Takeuchi K; Soda M; Mano H; Yasufuku K; Iizasa T
J Thorac Oncol; 2010 Dec; 5(12):2041-3. PubMed ID: 21102268
[No Abstract] [Full Text] [Related]
31. A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.
Zhong JM; Zhang GF; Lin L; Li DY; Liu ZH
Lung Cancer; 2020 Jul; 145():211-212. PubMed ID: 32409002
[No Abstract] [Full Text] [Related]
32. OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
Zhai X; Wu Q; Zeng Z; Suo J; Lin F; Zhou Q
Lung Cancer; 2021 Mar; 153():171-173. PubMed ID: 33483163
[No Abstract] [Full Text] [Related]
33. [A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].
Yuan Y; Wang Z; Nie X; Zhang P; Li L
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):696-700. PubMed ID: 36172736
[TBL] [Abstract][Full Text] [Related]
34. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
35. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and Prognostic Significance of the EML4-ALK Translocation and IGFR1, TTF1, Napsin A Expression in Patients with Lung Adenocarcinoma.
Bulutay P; AkyÜrek N; MemiŞ L
Turk Patoloji Derg; 2021; 37(1):7-17. PubMed ID: 32876329
[TBL] [Abstract][Full Text] [Related]
37. A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
Qiu H; Li Q; Xiao Y; Wu D; Meng R
J Thorac Oncol; 2021 Apr; 16(4):e21-e23. PubMed ID: 33781445
[No Abstract] [Full Text] [Related]
38. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
Lung J; Lin YC; Hung MS; Jiang YY; Lee KD; Lin PY; Tsai YH
Lung Cancer; 2016 Apr; 94():114-20. PubMed ID: 26973216
[TBL] [Abstract][Full Text] [Related]
39. [ALK inhibitor].
Mano H
Gan To Kagaku Ryoho; 2011 Jan; 38(1):27-30. PubMed ID: 21368458
[TBL] [Abstract][Full Text] [Related]
40. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.
Togashi Y; Soda M; Sakata S; Sugawara E; Hatano S; Asaka R; Nakajima T; Mano H; Takeuchi K
PLoS One; 2012; 7(2):e31323. PubMed ID: 22347464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
